appreciate our and affected every We acknowledge our continued patients or of this those thanks, coronavirus during very joining to been support ensure take to and concern is for and everyone, your Thanks, BIOLASE. express interest we to I heartfelt us precaution directly have afternoon. of Todd, again difficult impact The that want and customers, time. safety well-being foremost to employees, concerned, our continue this their their indirectly. and partners of the
levels. when unprecedented operations. is While possible, will soon virus specifically, too has market the time it our of an unknowns and dental normal significant more so the mitigated most. remain, predict impact is we as And a for hope first commercial impact the many It is difficult as on quarter it activities to return to negative had
in the closed some in for offices by dental Most XX%. procedures production and except and dental remained impacting emergency globally March U.S. close
which of in is few March, we first As lasers the our very month strongest such, quarter. sold historically
trial quickly our audiences. program. WME the in registered Zoom our over to and requesting However, Starting in date webinars team over over hosting our X,XXX XXX to participants, pivoted March, over follow-up XX,XXX target online with webinars XX interested webinar to launched reach series, we
not, another over expected. planned similar, with have We next X if greater webinars weeks few the participation
benefits this diminish While to raise our it ability ability impacted not have to of allowed awareness environment sell lasers, challenging we has the to our our of products.
services site. or the and that group reaffirm a the will expand possible. ways because aerosols team healthy prospects reduction can DSOs on guidelines office. look important and recoup these interact our I survey new as to to within general losing to want BIOLASE revenue a is to DSOs well looking expand technology still ways for we with the the build meet these believe from our are they sales helpful still large eagerly fit a Post practices practitioners once as to keep funnel ADA during even opportunity for data of as is positioned for more better this webinars much dental their to ahead is Furthermore, and be for in pandemic. they sales And in-house were revenue GPs
commercial addition discuss In this or reduction. our we efforts, took his The remarks. through in to in organization a action John more pivoting been downturn. our temporarily impacted structure cost reduce to entire has prepared salary will furlough this
of The the versus by day. open surgery on now the is of as periodontitis patient-reported as clinical McGuire much-awaited Institute performed traditional Waterlase-assisted flat to released study landmark gum efficacy well any treatment expected be outcomes
general appropriate establish for new this deliver mentioned, tissue of and previously our to surgery from this suffer protocols information drive peri study markets. disease, mention million Americans believe will specialists both perio not adoption for who all further the As and practitioner, study in target lasers the will we XX the
disease are perio UCLA. treating Columbia, about this We equally from excited to studies expected Harvard, and on additional be year released
least back at offices, some these work, to for actions forward. getting as to roll As support we industry plans closely our monitor share we XXXX of the these
is due step COVID-XX. mandatory from understand revenue many to First We lost this. acknowledging have the shutdown offices that
We will generate training which a those will make need dentists is that a get in-office dentists our use also This to have XXXX. and the offices feet. launched component provide to payment for on back financing Partnership revenue allow to Program travel. help It program single eliminates technology, until the program BIOLASE their BPP, titled not
us to also focus The BPP continues program further be will the for which market, us. penetrate a DSO help
laser pilots FDA look of therapy XXXX, due Clear additional to our ADA's on with Waterlase will the clearance for us. our recommendation scaling with to to manual dentists. COVID-XX for Phase bacterial is the DSOs with DSO pilot across Heartland Phase With other have we just planned use Based North trial example. program is additional was II also expand America. incorporate which Choice delayed reduction success, plan we The one now I In lasers many more of diode timely for reduction, aerosol treatment. recent Heartland,
our the the first to This WME. training In we puts our or group while Experience our focus in Waterlase allowing to office with technology addition on to firsthand environment, use their have power to our allowing prior DSO a dentists Mentoring technology the develop purchase. Waterlase by program continue use them market, firsthand and experience in showing to of learning post to them training technology mentors experienced of applications
U.S. increase shutdown by recent quarter, once to half webinar WME We XXXX. sales to return to expect WME could Our COVID-XX the and and X on we that this the equipment our is series normal. believe up Based confirmed year. program through key cities A things popularity these initiative success, to for to our WME during generate in initiated this early programs first prior program. XXXX to the demand of expand select
our once we're time sales the home to Even in what our open is support COVID-XX, of we territories, fight new to and crisis, environment, reps drain this will forward from some to global returns come leveraging new to that vital sales these current together we U.S. it reps. pleased that and normalcy. am that I to In look available, the pandemic, produce tool business doing. this is level and filled of prior ramp the we continue up revenue every report to we against all environment, had lift
of critical the an closed this registered and And the portable State most have ventilators Use the supply Emergency So for approval we the intensive emergency continue an MEK unit received for BIOLASE's be to need during operate, FDA part, California. facility its and to to while ICU-grade COVID-XX to ventilator Authorization. supply of joined against authorization COVID-XX use FDA because under exemption and most care is office through to fight with of market by the in manufacture ventilator California product. product dental pandemic, BIOLASE manufacturer this MEK-ICS, received manufacture the this FDA partnering is
million date, portion in ventilator the We supply able a we and distributing deliver experience BIOLASE FDA-cleared $XX of to in medical will that manufacturing crisis. month. equipment orders, we leverage these MEK years orders have the COVID-XX will received hopeful during of ventilators support next and be to and in are help To
chain with the imagine, can is you players this market, pressure. in under now As GM component like supply large
past it in services to rest normalcy, for And some sustainable some over have of the and our will allowing positive BIOLASE up, for circumstances, years opening are be made know our to and and out build current confident businesses are to states see that that excited and healthier we bench long-term year past positioned to We improve performed. be glad profitable how international play operating cost changes growth. very revenue to created of have the front of all talent dental While we return once we continue U.S. now us level X.X is structure and are a company. about opportunity market many to impossible XXXX given the believe
John? over in now detail. I'll John financial first quarter said, that With review turn it to to results our more
